Big tech companies invest billions in health research. News feature from Paul Webster.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser . In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Nature's Nano-Syringes: Harnessing Bacterial Machines for Next-Gen MedicineBacterial Injection System Delivers Proteins in Mice and Human Cells With further development, the programmable system could be used in a range of applications including gene therapy and cancer therapy. Researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Re
Consulte Mais informação »
A Sleep Medicine Specialist Says These 7 Cooling Pillows Can Prevent Night SweatsThe best cooling are made of shredded memory foam, latex, or other cooling materials that wick away moisture and keep you sweat-free.
Consulte Mais informação »
It’s different for each person, but sometimes the best medicine is an extra pushIt’s different for each person, but sometimes the best medicine is an extra push to get outside, writes Alaska outdoors columnist Alli Harvey.
Consulte Mais informação »
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial - Nature MedicineIn a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.
Consulte Mais informação »
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial - Nature MedicineIn a phase 2 trial, the combination of chemotherapy with durvalumab, an anti-PD-L1 antibody, exhibited promising clinical activity in patients with previously untreated, unresectable mesothelioma, with additional analyses providing insights into genomic and immunologic features potentially associated with response.
Consulte Mais informação »
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i - Nature MedicineAnalyses from the COMBI-i trial evaluating PD-1, BRAF and MEK inhibition in patients with metastatic melanoma demonstrate high response rates and uncover molecular correlates of long-term treatment benefit. Trial led by AACR23 speaker Reinhard Dummer
Consulte Mais informação »